Sugi Predict

Sugi Predict / Compounds / SCHEMBL436968

SCHEMBL436968

SCHEMBL436968

Cc1cccc(C)c1CC(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ CA2 P00918 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SLC22A12 Q96S37 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ SIRT1 Q96EB6 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ MYC P01106 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28039022 0.88 PLA2G2A (0.47) PLA2G2AHTTCA2KDM4EMAPT
SCHEMBL1827626 0.86 PTGS2 (0.42) PLA2G2ASLC22A12ALDH1A1HSD17B10
SCHEMBL2820273 0.83 GABRA1 (0.48) CA2MEN1KMT2ASLC22A12SMN1; SMN2
SCHEMBL15998124 0.82 ALDH1A1 (0.35) PLA2G2AHTTCA2KDM4EMAPT
SCHEMBL10710444 0.82 RORC (0.41) KDM4EMEN1GAAKMT2ASMN1; SMN2
SCHEMBL10713069 0.82 MAPT (0.43) PLA2G2AHTTMAPTMEN1GAA
SCHEMBL12214127 0.81 KDM4E (0.42) KDM4EMAPTMEN1GAAKMT2A
SCHEMBL31377046 0.80 TDP1 (0.53) PLA2G2AKDM4EMAPTMEN1KMT2A
SCHEMBL1004574 0.79 KDM4E (0.58) KDM4EMAPTMEN1GAAKMT2A
SCHEMBL15304521 0.79 KDM4E (0.41) KDM4EMAPTMEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103664829-A Ranolazine synthesis technology CHENGDU YILUKANG MEDICAL TECHNOLOGY & SERVICE CO LTD 2014-03-26 — — CN claimed
CN-103570645-A Method for preparing N-(2,6-dimethyl phenyl)-2-(1-piperazine)acetamide SHANGHAI DESANO CHEMICAL PHARM 2014-02-12 — — CN claimed
EP-1326613-A1 USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO 1,2-A]PYRIMIDINE AND IMIDAZO 1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS Grünenthal GmbH (DE) 2003-07-16 — — EP claimed
WO-2002030428-A1 USE OF SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-, IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS Grünenthal GmbH (DE) 2002-04-18 — — WO claimed
EP-4598546-A1 TOPICAL COMPOSITIONS COMPRISING EMULSIFIED POVIDONE IODINE SOLUTIONS AND METHODS OF PREPARATION Kojian, MD, James (US) 2025-08-13 — — EP disclosed
WO-2025080295-A1 TOPICAL COMPOSITIONS COMPRISING EMULSIFIED POVIDONE IODINE SOLUTIONS AND METHODS OF PREPARATION KOJIAN MD JAMES (US) 2025-04-17 — — WO disclosed
CN-111995539-B Preparation method of lidocaine hydrochloride impurity E 郑州原理生物科技有限公司 2023-08-11 — — CN disclosed
CN-111995539-B Preparation method of lidocaine hydrochloride impurity E 郑州原理生物科技有限公司 2023-08-11 — — CN disclosed
US-20220079978-A1 METHOD OF TREATING OR AMELIORATING SKIN CONDITIONS WITH A MAGNETIC DIPOLE STABILIZED SOLUTION REVEN PHARMACEUTICALS, INC. (US) 2022-03-17 — — US disclosed
US-11202798-B2 Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution REVEN PHARMACEUTICALS, INC. (US) 2021-12-21 — — US disclosed
CN-111995539-A Preparation method of lidocaine hydrochloride impurity E 郑州原理生物科技有限公司 2020-11-27 — — CN disclosed
CN-111995539-A Preparation method of lidocaine hydrochloride impurity E 郑州原理生物科技有限公司 2020-11-27 — — CN disclosed
EP-1482791-A1 ANTIMICROBIAL THERAPEUTIC COMPOSITIONS AND METHODS OF USE Pharmessen Scientific, Inc. (US) 2004-12-08 — — EP disclosed
WO-2003069993-A1 ANTIMICROBIAL THERAPEUTIC COMPOSITIONS AND METHODS OF USE PHARMESSEN SCIENTIFIC, INC. (US) 2003-08-28 — — WO disclosed
US-5753644-A Vasopressin antagonist and oxytocin antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-05-19 — — US disclosed
US-5622947-A VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-22 — — US disclosed
EP-0514667-B1 Benzazepin derivatives as vasopressin antagonists OTSUKA PHARMA CO LTD (JP) 1995-08-09 — — EP disclosed
EP-0620003-A1 VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-10-19 — — EP disclosed
US-5244898-A Vasopressin antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-09-14 — — US disclosed
EP-0514667-A1 Benzazepin derivatives as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11202798-B2 Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution KIT, CUTA, MEN1 PLA2G2A 4299/4885HTT 2958/4885CA2 750/4885
US-20220079978-A1 METHOD OF TREATING OR AMELIORATING SKIN CONDITIONS WITH A MAGNETIC DIPOLE STABILIZED SOLUTION KIT, CUTA, MEN1 PLA2G2A 4299/4885HTT 2958/4885CA2 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.